Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HZ-R078
- Development stage
- Preclinical
- Lead developer
- HealZen Therapeutics
01
Overview
HZ-R078: sourced facts only. name: "HZ-R078 is a novel selective STAT3 degrader which exhibits long-lasting STAT3 degradation effect in tumor tissue, while the clearance in plasma and other organs are high." [DOI:10.1158/1538-7445.am2023-3109]; target: "HZ-R078 is a novel selective STAT3 degrader which exhibits long-lasting STAT3 degradation effect in tumor tissue, while the clearance in plasma and other organs are high." [DOI:10.1158/1538-7445.am2023-3109]; developer: "1HealZen Therapeutics Co., Ltd., Hangzhou, China." [DOI:10.1158/1538-7445.am2023-3109]; stage: "In in-vivo anti-tumor evaluation, HZ-R078 can significantly suppress the growth of tumor in SU-DHL1 and Karpass299 models in a weekly administration." [DOI:10.1158/1538-7445.am2023-3109]
02
Targets
STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on HZ-R078.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HZ-R078.